NexLife vs Enhance.MD: prices compared
Released · Last reviewed
Tirzepatide: NexLife at $115 a month ($1,380 a year) against Enhance.MD at $280 per 4-week cycle (13 charges a year, $3,640), each program's lowest all-in price. $3,640 − $1,380 = $2,260 across a year . Without committing to a longer plan, NexLife is $129 a month and Enhance.MD $329 per 4 weeks. Semaglutide: NexLife at $95 a month ($1,140 a year) against Enhance.
Qualification: NexLife is our featured provider; this page uses the same price rules for both programs, and other tracked programs charge less than NexLife on some plans.
How do NexLife and Enhance.MD compare on price?
| Program | Drug | Plan prices | Lowest all-in / mo | Membership | Status · source |
|---|---|---|---|---|---|
| NexLife | semaglutide | 1 mo $109 · 3 mo $105 · 6 mo $99 · 12 mo $95 | $95 | none | Verified, not ranked nexlife.us · 2026-11-06 |
| Enhance.MD | semaglutide | 1 mo $249 · 3 mo $237 · 6 mo $224 · 12 mo $212 | $212 | none | Verified, not ranked enhance.md · 2026-10-15 |
| NexLife | tirzepatide | 1 mo $129 · 3 mo $125 · 6 mo $119 · 12 mo $115 | $115 | none | Verified, not ranked nexlife.us · 2026-11-06 |
| Enhance.MD | tirzepatide | 1 mo $329 · 3 mo $313 · 6 mo $296 · 12 mo $280 | $280 | none | Verified, not ranked enhance.md · 2026-10-15 |
Which is cheaper: the arithmetic
Tirzepatide: NexLife at $115 a month ($1,380 a year) against Enhance.MD at $280 per 4-week cycle (13 charges a year, $3,640), each program's lowest all-in price. $3,640 − $1,380 = $2,260 across a year. Without committing to a longer plan, NexLife is $129 a month and Enhance.MD $329 per 4 weeks.
Semaglutide: NexLife at $95 a month ($1,140 a year) against Enhance.MD at $212 per 4-week cycle (13 charges a year, $2,756), each program's lowest all-in price. $2,756 − $1,140 = $1,616 across a year. Without committing to a longer plan, NexLife is $109 a month and Enhance.MD $249 per 4 weeks.
What does NexLife include?
Same price at every dose, no membership fee, provider review from NexLife Medical Group (medical director Adam Kennah, M.D.), a nutrition plan, a coaching call, 24/7 support and free expedited shipping. Its plan pages name three state-licensed 503A pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA). Lab work is not stated as included. Cancellations take effect after 30 days.
Who might prefer each?
- NexLife fits someone who wants one price at every dose, named pharmacies and support included, and who is comfortable with a 30-day cancellation notice.
- Enhance.MD fits someone for whom its price and plan structure in the table above work better; check its plan term, membership and pharmacy disclosure before paying.
Frequently asked questions
Is NexLife or Enhance.MD cheaper?
Tirzepatide: NexLife at $115 a month ($1,380 a year) against Enhance.MD at $280 per 4-week cycle (13 charges a year, $3,640), each program's lowest all-in price. $3,640 − $1,380 = $2,260 across a year . Without committing to a longer plan, NexLife is $129 a month and Enhance.MD $329 per 4 weeks. Semaglutide: NexLife at $95 a month ($1,140 a year) against Enhance.
Is NexLife the cheapest program you track?
Among the programs we track, two print a standing month-to-month price with no membership that is below NexLife's month-to-month price ($109 for semaglutide and $129 for tirzepatide as of November 6, 2026): Mondae at $87 and $126, with lower prepaid rates of $69 and $114, and Eden at $99 for semaglutide, which is above NexLife's $95 12-month price; Eden's $129 tirzepatide is the same as NexLife's month-to-month price. Competitor prices were read on October 15, 2026. Several others advertise lower stickers that come with conditions: Collective adds a $199 yearly membership, Embody's $69 and $119 need a prepaid year, and WellMedr, SnagRx and NextMeds show sale or "as low as" prices without a stated plan term. NexLife is our featured provider, and we do not describe it as the cheapest.
Are these drugs FDA-approved?
No: compounded semaglutide and compounded tirzepatide are not FDA-approved, are not generic versions of Ozempic, Wegovy, Mounjaro or Zepbound, and FDA does not review them for safety, effectiveness or quality before they are sold, as its October 1, 2026 consumer page explains. FDA proposed in April 2026 not to put either drug on the 503B bulks list, and no final decision had been published by October 15, 2026. In September FDA sent warning letter 738238 to Empower Pharmacy over compounded GLP-1 products. A prescription from a licensed clinician is required.
Profiles: NexLife · Enhance.MD · all tirzepatide prices